Abstract PD08-03: Competing Causes of Mortality vs. Breast Cancer Mortality at 5-Years among 9766 Postmenopausal Women with Hormone Receptor Positive Early Breast Cancer Treated on the TEAM Study of Adjuvant Hormonal Therapy

2010 ◽  
Author(s):  
SE Jones ◽  
H Putter ◽  
A Hasenburg ◽  
CJH van de Velde ◽  
D Rea ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Postmenopausal Women ◽  
Hormonal Therapy ◽  
Cancer Mortality ◽  
Hormone Receptor ◽  
Breast Cancer Mortality ◽  
Adjuvant Hormonal Therapy ◽  
Hormone Receptor Positive ◽  
Causes Of Mortality ◽  
Competing Causes

The Aromatase Inhibitors as Adjuvant Therapy for Hormone Receptor-Positive Breast Cancer

2003 ◽  
Vol 1 (2) ◽  
pp. 215-221
Author(s):  
Jennifer A. Ligibel ◽  
Eric P. Winer
Keyword(s):  
Breast Cancer ◽  
Aromatase Inhibitors ◽  
Hormonal Therapy ◽  
Hormone Receptor ◽  
Uterine Cancer ◽  
Adjuvant Hormonal Therapy ◽  
Adjuvant Setting ◽  
Modest Improvement ◽  
Hormone Receptor Positive ◽  
Positive Breast Cancer

Adjuvant hormonal therapy has been shown to decrease the risk of breast cancer recurrence and overall mortality in patients with hormone receptor-positive breast cancer. Tamoxifen has been used in this setting for many years, both in premenopausal and postmenopausal patients. Tamoxifen is not devoid of toxicity, and attempts have been made to develop newer hormonal agents with better efficacy and less toxicity. The aromatase inhibitors have shown equivalent or superior efficacy to tamoxifen in the treatment of metastatic breast cancer, and efforts are underway to determine the role of these agents in early breast cancer. The ATAC trial recently showed that use of the third-generation aromatase inhibitor anastrozole in the adjuvant setting led to a modest improvement in relapse-free survival as compared with tamoxifen. Patients treated with anastrozole were also less likely to develop uterine cancer or experience a thromboembolic event. However, patients treated with anastrozole were more likely than those treated with tamoxifen to suffer a fracture or other musculosketal problem. An ASCO technology assessment panel reviewed the relevant data and issued a consensus statement regarding the use of aromatase inhibitors in the adjuvant setting. In general, the panel favored the continued use of tamoxifen as adjuvant hormonal therapy for most postmenopausal women. Within the next few years, further data from the ATAC trial and from other trials of aromatase inhibitors in the adjuvant setting should be available to guide treatment recommendations for this patient population.

scholarly journals Practical consensus recommendations on duration of adjuvant hormonal therapy in breast cancer

2018 ◽  
Vol 07 (02) ◽  
pp. 142-145 ◽  
Author(s):  
S. Gupta ◽  
M. Singh ◽  
Amish Vora ◽  
G. Babu ◽  
M. Walia ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Hormonal Therapy ◽  
Hormone Receptor ◽  
Early Stage ◽  
Adjuvant Hormonal Therapy ◽  
Breast Cancer Patients ◽  
Term Survival ◽  
Consensus Recommendations ◽  
Hormone Receptor Positive

AbstractOptimization of adjuvant systemic therapy in women with early-stage hormone receptor-positive breast cancer includes the consideration of chemotherapy and duration of hormone therapy. Adjuvant hormonal therapy significantly improves long-term survival of breast cancer patients with hormone receptor-positive disease. Despite the proven clinical efficacy of tamoxifen and aromatase inhibitors, many breast cancer survivors either fail to take the correct dosage at the prescribed frequency (adherence) or discontinue therapy (persistence). Expert oncologist discussed on the duration of adjuvant hormonal therapy for improvement of OS and quality of life of breast cancer patients by providing reduction in recurrence and mortality. This expert group used data from published literature, practical experience and opinion of a large group of academic oncologists to arrive at this practical consensus recommendations for the benefit of community oncologists.

Abstract A52: Receipt of adjuvant hormonal therapy among Medicaid enrollees diagnosed with hormone-receptor positive breast cancer, 2004-2007.

2012 ◽  
Author(s):  
Tisha M. Felder ◽  
Lincy S. Lal ◽  
Dana Stafkey-Mailey ◽  
Phoenix Do ◽  
Kevin Lu ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Hormonal Therapy ◽  
Hormone Receptor ◽  
Adjuvant Hormonal Therapy ◽  
Hormone Receptor Positive ◽  
Positive Breast Cancer

scholarly journals Non-initiation of adjuvant hormonal therapy in women with hormone receptor-positive breast cancer: The Breast Cancer Quality of Care Study (BQUAL)

2012 ◽  
Vol 134 (1) ◽  
pp. 419-428 ◽  
Author(s):  
Alfred I. Neugut ◽  
Grace Clarke Hillyer ◽  
Lawrence H. Kushi ◽  
Lois Lamerato ◽  
Nicole Leoce ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Quality Of Care ◽  
Hormonal Therapy ◽  
Hormone Receptor ◽  
Adjuvant Hormonal Therapy ◽  
Hormone Receptor Positive ◽  
Care Study ◽  
Positive Breast Cancer

scholarly journals Weakly hormone receptor– positive breast cancer and use of adjuvant hormonal therapy

2013 ◽  
Vol 20 (6) ◽  
pp. 612 ◽  
Author(s):  
C.M. Lin ◽  
J. Jaswal ◽  
T. Vandenberg ◽  
A. Tuck ◽  
M. Brackstone
Keyword(s):  
Breast Cancer ◽  
Hormonal Therapy ◽  
Hormone Receptor ◽  
Adjuvant Hormonal Therapy ◽  
Hormone Receptor Positive ◽  
Positive Breast Cancer
Sign in / Sign up

Export Citation Format

Share Document